+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites



Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites



Therapeutic Drug Monitoring 21(2): 166-170



Concentrations of the enantiomers of unconjugated and of total (unconjugated plus conjugated) mianserin, desmethylmianserin and 8-hydroxymianserin were measured in 12 patients before and after the introduction of carbamazepine. The dose of mianserin was 60 mg/d, carbamazepine was coadministered at 400 mg/d for 4 weeks, and blood samples were taken at weekly intervals after the introduction of carbamazepine. Each week, carbamazepine significantly decreased plasma concentrations of unconjugated and total (S)-mianserin (the more potent enantiomer) and of unconjugated and total (R)-mianserin. On average, plasma concentrations of unconjugated and total (S)-mianserin and of unconjugated and total (R)-mianserin were 55%, 56%, 66%, and 55%, respectively, of the corresponding values before introduction of carbamazepine. These results strongly suggest the involvement of CYP3A4, the major CYP enzyme induced by carbamazepine, in the metabolism of both enantiomers of mianserin. A strong decrease in the concentrations of (S)-8-hydroxymianserin was also measured (on average, the concentrations were 69% of the corresponding values before carbamazepine introduction). Conversely, plasma concentrations of unconjugated and of total (S)-desmethylmianserin, (R)-desmethylmianserin, and (R)-8-hydroxymianserin were only slightly modified by carbamazepine. From a clinical point of view, as a therapeutic window for (S)-mianserin has been recently suggested, the dose of racemic mianserin for a patient whose (S)-mianserin concentrations have been stabilized within this therapeutic window would need to be approximately doubled if carbamazepine, at 400 mg/d, is introduced as a comedication.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010547206

Download citation: RISBibTeXText

PMID: 10217335


Related references

Effects of carbamazepine coadministration on free and total serum concentrations of imipramine and its metabolites. European Journal of Clinical Pharmacology 52(Suppl. ): A141, 1997

The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. Journal of Clinical Psychopharmacology 17(6): 467-471, 1997

Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Therapeutic Drug Monitoring 18(2): 164-167, 1996

Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics 7(5): 369-374, 1997

Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clinical Pharmacology & Therapeutics 50(1): 10-15, 1991

Subjective side effects of mianserin in relation to plasma concentrations of mianserin and demethylmianserin. Therapeutic Drug Monitoring 14(3): 190-193, 1992

Subjective Side Effects of Mianserin in Relation to Plasma Concentrations of Mianserin and Desmethylmianserin. Therapeutic Drug Monitoring 14(3): 190-193, 1992

Determination of the enantiomers of mianserin, desmethylmianserin, and 8-hydroxymianserin in the plasma and urine of mianserin-treated patients. Chirality 6(7): 555-563, 1994

Comparison of the effects of mianserin and its enantiomers and metabolites on a behavioral screen for antidepressant activity. Psychopharmacology 105(4): 453-458, 1991

Steady-state plasma concentrations of mianserin and its major active metabolites, demethylmianserin. Therapeutic Drug Monitoring 15(2): 113-117, 1993

Prediction of plasma concentrations of mianserin and demethylmianserin at steady state from those after an initial dose of mianserin. Therapeutic Drug Monitoring 15(2): 118-121, 1993

Prediction of Plasma Concentrations of Mianserin and Desmethylmianserin at Steady State from Those After an Initial Dose of Mianserin. Therapeutic Drug Monitoring 15(2): 118-121, 1993

The potential therapeutic role of the enantiomers and metabolites of mianserin. British Journal of Clinical Pharmacology 15(Suppl. 2): 269s-276s, 1983

Effects of progabide on carbamazepine epoxide and carbamazepine concentrations in plasma. Epilepsia 25(5): 674, 1984

The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites. British Journal of Clinical Pharmacology 29(6): 763-765, 1990